Chapter 219: Raw Data
Thomas Alvarez stopped outside the grand jury door long enough for Leah to hear the hesitation through the corridor wall. One pause, one breath, one hand shifting a folder. Deborah Kowalski had given the jurors James Voss's warning; Thomas was about to give them the reason that warning had turned lethal. Catherine's hand found the edge of the witness-room table and held there until her knuckles changed color.
Okafor stood near the speaker, not sitting, his legal pad tucked against his ribs. The black line he had written still faced Leah from the table: Raw data manipulation. It looked too small for what it carried. Numbers had been changed. Patients had been endangered. James had noticed. Martha's Foundation had treated that discovery like a death sentence.
The door opened in the grand jury room.
"State your name for the record," ADA Flores said.
"Thomas Alvarez," the man answered. His voice was lower than Deborah's, steadier at first, but it carried the careful control of someone who had spent years deciding whether memory was safer than speech. "I was a lab technician at Mount Sinai from 1999 to 2003. I worked in clinical research with Dr. James Voss."
Catherine closed her eyes at James's name.
Flores guided him to 2001. "What was Dr. Voss reviewing?"
"A Phase III clinical trial for a neurodegenerative disease treatment," Thomas said. "The trial was funded by the Thorne Foundation through a grant to Mount Sinai."
Leah heard paper move, then Thomas swallow. He did not sound like a man reciting a report. He sounded like a man walking back into a lab at midnight, fluorescent light over spreadsheets, James beside him refusing to look away.
"The treatment group looked too successful," Thomas continued. "Better survival, slower symptom progression, improved quality-of-life measures. Every metric moved in the same direction. That is not how clinical data behaves when it is messy and real."
Okafor's pen stopped.
Thomas said, "James asked for the raw data."
The witness room seemed to tighten around Leah. She knew what raw data meant now. Before this year it would have been a sterile phrase, something locked in medical offices and grant files. Here it was the place where someone's lie either survived or died.
"What did he find?" Flores asked.
"Outcome measurements had been altered," Thomas said. "Not a single clerical correction. A pattern. Adjustments that made the treatment appear more effective than it was. James re-ran the verification tests. I watched him do it twice because he did not want to accuse anyone without proof."
Catherine whispered, "He wouldn't."
Leah looked at her.
"James would check and check," Catherine said, barely audible. "He hated being wrong more than he hated being afraid."
In the grand jury room, Thomas's testimony sharpened. James had compared control groups, treatment groups, trial protocols, patient files. The anomaly stayed. The same favorable direction appeared in other Foundation-funded trials. Not every number was false, Thomas said. That was what made it dangerous. Enough truth had been left in place to make the lie look like science.
Leah felt the first hard click of understanding. Martha had not only stolen money through the Foundation. She had built reputation, medical influence, and corporate value on manipulated human outcomes. James had threatened more than a family secret. He had threatened an empire that wore charity as a lab coat.
"Did Dr. Voss believe the manipulation was isolated?" Flores asked.
"No," Thomas said. "He told me it was systemic. He said Foundation trials were showing the same directional anomalies across multiple studies."
Okafor wrote one word on the pad and angled it toward Leah.
Systemic.
There was the reward, cold but undeniable: the motive no defense attorney could soften into family drama. James Voss had not been killed because he was inconvenient to a custody story. He had been killed because he could expose a research fraud network that tied money, hospitals, grants, and Martha's authority together.
"What did Dr. Voss do next?" Flores asked.
"He filed an IRB complaint in November 2001," Thomas said. "He included verification tests, trial protocols, and the raw data. He named the manipulated results."
"Was he warned?"
"Yes." Thomas's voice roughened. "He told me Dr. Samuel Reinhardt warned him not to pursue it. James said the warning included career consequences and consequences for his family."
Leah's stomach tightened around Deborah's phrase. Some doors, once opened, can't be closed. She wondered if Thomas had heard the exact words or only seen what the words did to James afterward.
Thomas answered the question she had not spoken. "After that, James changed. He checked the hallway before leaving the lab. He asked me not to discuss the data over hospital phones. In December, he said he was being followed. He said anonymous callers told him to withdraw the complaint."
Catherine pressed one fist to her mouth.
Flores gave Thomas a moment, then asked, "What was happening in Dr. Voss's family at that time?"
"Elena Voss was pregnant," Thomas said. "Seven months, around then. James was terrified the pressure would touch her."
Leah had to look down. She had known Elena as a name in documents, a photograph, a locket, Catherine's grief. Now she saw her as a pregnant woman waiting at home while James carried a lab notebook that had made powerful people furious.
"What happened to the complaint?" Flores asked.
"On January fifteenth, 2002, James told me the IRB had dismissed it. The stated reason was insufficient evidence."
Thomas let the words sit for a second, and Leah heard the contempt under his control.
"Was that accurate?"
"No. The evidence existed. I had watched him assemble it. The dismissal was political."
Okafor glanced at the marshal by the door, then back to the speaker. Flores did not rush. She took Thomas through the lab notebook, the later anomalies, the way James kept working after being dismissed because the data still showed harm. By the time Thomas reached the final answer, his professional calm had cracked enough for grief to show through.
"I am testifying that James Voss discovered systematic manipulation in Thorne Foundation-funded clinical trials," he said. "I am testifying that the IRB dismissal was not an evidence review. And I am testifying that these findings preceded the deaths of James and Elena Voss."
The silence afterward was longer than Deborah's. Leah could not see the jurors, but she could feel the room on the other side absorbing the shape of it: fraud, warning, dismissal, surveillance, death, custody theft. One chain. One motive.
Catherine lowered her fist. "James wasn't paranoid."
"No," Leah said. "He was early."
Okafor's eyes moved to her, approving the precision even though the word hurt. Early meant alone. Early meant no institution had stood beside him when the threat first appeared. Early meant Martha had years to bury what he found.
The grand jury door opened again. Thomas's footsteps left the room. Another set approached almost immediately, lighter, quick, stopping twice as if the witness had nearly turned back.
Okafor listened to his earpiece. "Jennifer Walsh," he said. "Former Thorne Group legal department."
Leah looked up.
"Board minutes?" Catherine asked.
"Board minutes," Okafor said. "October 2002. The corporate cover-up."
Leah stared at the closed door as Jennifer Walsh entered. Thomas had shown why James became dangerous. Jennifer would have to show what Martha did after he was dead.